Last reviewed · How we verify

Superiority of augmented repairs

Applied Biologics, LLC · Phase 1 active Biologic

Superiority of augmented repairs is a Biologic drug developed by Applied Biologics, LLC. It is currently in Phase 1 development. Also known as: FlōGraft®, Human amniotic fluid-derived allograft.

At a glance

Generic nameSuperiority of augmented repairs
Also known asFlōGraft®, Human amniotic fluid-derived allograft
SponsorApplied Biologics, LLC
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Superiority of augmented repairs

What is Superiority of augmented repairs?

Superiority of augmented repairs is a Biologic drug developed by Applied Biologics, LLC.

Who makes Superiority of augmented repairs?

Superiority of augmented repairs is developed by Applied Biologics, LLC (see full Applied Biologics, LLC pipeline at /company/applied-biologics-llc).

Is Superiority of augmented repairs also known as anything else?

Superiority of augmented repairs is also known as FlōGraft®, Human amniotic fluid-derived allograft.

What development phase is Superiority of augmented repairs in?

Superiority of augmented repairs is in Phase 1.

Related